Global burden of liver disease: 2023 update

Devarbhavi, Harshad; Asrani, Sumeet K.; Arab, Juan Pablo; Nartey, Yvonne Ayerki; Pose, Elisa; Kamath, Patrick S.

doi:10.1016/j.jhep.2023.03.017

Cited by 425 publications

(202 citation statements)

References 275 publications

Supporting

Mentioning

138

Contrasting

Order By: Relevance

“…Hepatocellular carcinoma (HCC) is a life-threatening disease, which is the fourth leading cause of cancer-related deaths worldwide and the second leading cause of cancerrelated deaths in men [1]. Due to late diagnosis, most HCC patients are ineligible for curative therapies, such as surgical resection [2].…”

Section: Introductionmentioning

confidence: 99%

Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

Tajiri,

Tsukada,

Tokimitsu

et al. 2023

Oncology

View full text Add to dashboard Cite

Introduction: Atezolizumab plus bevacizumab (Atez/Bev) is a standard treatment for unresectable hepatocellular carcinoma (HCC) due to its good antitumor and survival prolongation effects. Post-progression survival (PPS) has been reported to be a great contributor in the treatment with tyrosine kinase inhibitors for unresectable HCC. This study aimed to clarify the significance of progression-free survival (PFS) or PPS of Atez/Bev treatment for HCC. Methods: We analyzed the correlations of PFS and PPS with overall survival (OS) in studies of HCC patients treated with Atez/Bev and evaluated the contribution to OS in Atez/Bev treatment with patients at our institutions as clinical practice. Results: Analysis of 18 studies involving 3,752 patients treated with Atez/Bev found that PPS had a stronger correlation with OS (R2 = 0.872, p < 0.001) than did PFS (R2 = 0.605, p = 0.001). Analysis of 80 patients with unresectable HCC treated with Atez/Bev found that presence of antitumor responses during Atez/Bev was the most significant contributor to OS, and post-progression treatment after Atez/Bev also significantly contribute to OS. Conclusion: The presence of antitumor response with tumor shrinkage during Atez/Bev treatment contributes to good OS through its durable response. Atez/Bev treatment could be considered as first-line treatment for unresectable HCC. However, there is a need for optimal biomarkers for good antitumor response.

show abstract

Section: Introductionmentioning

confidence: 99%

Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

Tajiri,

Tsukada,

Tokimitsu

et al. 2023

Oncology

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the disease carries an extremely poor prognosis, further exacerbating recovery. 4,5 Currently, treatment options for HCC are limited and primarily include surgical liver resection, chemotherapy, and liver transplantation. Early detection modalities for HCC are also restricted to the aforementioned options.…”

Section: Introductionmentioning

confidence: 99%

“…The majority of HCC cases occur in patients with underlying liver diseases, predominantly hepatitis B virus (HBV) or hepatitis C virus (HCV) infections or alcohol abuse. Unfortunately, the disease carries an extremely poor prognosis, further exacerbating recovery. , Currently, treatment options for HCC are limited and primarily include surgical liver resection, chemotherapy, and liver transplantation. Early detection modalities for HCC are also restricted to the aforementioned options .…”

Section: Introductionmentioning

confidence: 99%

Enhancing Targeted Therapy in Hepatocellular Carcinoma through a pH-Responsive Delivery System: Folic Acid-Modified Polydopamine-Paclitaxel-Loaded Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Nanoparticles

Wu,

Wang,

Peng

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Currently, there is an inherent contradiction between the multifunctionality and excellent biocompatibility of anticancer drug nanocarriers, which limits their application. Therefore, to overcome this limitation, we aimed to develop a biocompatible drug delivery system for the treatment of hepatocellular carcinoma (HCC). In this study, we employed poly(3-hydroxybutyrate-co-3hydroxyvalerate) (PHBV) as the fundamental framework of the nanocarrier and utilized the emulsion solvent evaporation method to fabricate nanoparticles loaded with paclitaxel (PTX), known as PTX-PHBV NPs. To enhance the tumortargeting capability, a dopamine self-polymerization strategy was employed to form a pH-sensitive coating on the surface of the nanoparticles. Then, folic acid (FA)-targeting HCC was conjugated to the nanoparticles with a polydopamine (PDA) coating by using the Michael addition reaction, resulting in the formation of HCC-targeted nanoparticles

show abstract

“…Alcohol consumption has increased over the COVID-19 pandemic, and this rise in alcohol consumption has led to increases in alcohol-associated liver disease and alcohol-associated hepatitis (AH) in particular 1 . The growing problem of AH has been exacerbated by the lack of suitable therapeutics to reverse AH, with many patients requiring liver transplants.…”

mentioning

confidence: 99%

“…

…”

mentioning

confidence: 99%

Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction

Mackowiak

Gao

2023

Hepatology

View full text Add to dashboard Cite

Activation of cholangiocyte mTORC1 drives alcoholinduced ductular reactionAlcohol consumption has increased over the COVID-19 pandemic, and this rise in alcohol consumption has led to increases in alcohol-associated liver disease and alcohol-associated hepatitis (AH) in particular. [1] The growing problem of AH has been exacerbated by the lack of suitable therapeutics to reverse AH, with many patients requiring liver transplants. The etiology of AH is complex, and current animal models of AH have not been able to replicate certain hallmarks of severe AH that correlate with prognosis, including ductular reaction (DR). This has greatly limited AH therapeutic development even though many targets and pathways have shown promise in preclinical models. In fact, several studies have shown that the mechanistic target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, energy metabolism, and autophagy, is activated in AH, and inhibition of mTORC1 can reverse ethanol-induced liver injury. [2] However, the effect of mTORC1 on alcohol-associated DR and its associated liver injury remains unknown. Some of the questions surrounding mTORC1 in alcohol-associated liver disease are answered in this issue of HEPATOLOGY by Chao et al. [3] Chao and colleagues detected increased mTORC1 activation in chronic-plus-binge ethanol-fed mouse and human AH liver samples, and such elevated mTORC1 activation is associated with decreased protein levels of tuberous sclerosis complex 1 (TSC1), a negative regulator of mTORC1. These findings led the authors to characterize ethanol-induced liver injury in liverspecific Tsc1 knockout (L-Tsc1 KO) mice that exhibit constitutive mTORC1 activation. Alanine transaminase levels were not different between wild-type (WT) and L-Tsc1 KO mice subjected to the control diet, indicating that baseline liver injury may not be different. However, L-Tsc1 KO mice on the control diet exhibited increased liver size, DR, fibrosis, and immune cell infiltration compared with their WT

show abstract

Global burden of liver disease: 2023 update

Cited by 425 publications

References 275 publications

Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

Enhancing Targeted Therapy in Hepatocellular Carcinoma through a pH-Responsive Delivery System: Folic Acid-Modified Polydopamine-Paclitaxel-Loaded Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Nanoparticles

Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction

Contact Info

Product

Resources

About